Form 8-K - Current report:
SEC Accession No. 0000950170-24-021081
Filing Date
2024-02-27
Accepted
2024-02-27 16:02:21
Documents
14
Period of Report
2024-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcvx-20240227.htm   iXBRL 8-K 40121
2 EX-99.1 pcvx-ex99_1.htm EX-99.1 190021
3 GRAPHIC img251305552_0.jpg GRAPHIC 9918
  Complete submission text file 0000950170-24-021081.txt   377090

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pcvx-20240227.xsd EX-101.SCH 26001
15 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-20240227_htm.xml XML 4927
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39323 | Film No.: 24686362
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)